Total Payments
$376,050
2024 Payments
$87,250
Companies
4
Transactions
72
Medicare Patients
22,173
Medicare Billing
$646,559
Payment Breakdown by Category
Consulting$354,450 (94.3%)
Research$21,600 (5.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $354,450 | 67 | 94.3% |
| Unspecified | $21,600 | 5 | 5.7% |
Payments by Type
General
$354,450
67 transactions
Research
$21,600
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $222,400 | 21 | $0 (2019) |
| AstraZeneca UK Limited | $131,050 | 44 | $0 (2024) |
| Celgene Corporation | $21,600 | 5 | $0 (2021) |
| Acerta Pharma LLC | $1,000 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87,250 | 9 | AstraZeneca UK Limited ($87,250) |
| 2023 | $20,600 | 7 | AstraZeneca UK Limited ($20,600) |
| 2022 | $10,500 | 9 | AstraZeneca UK Limited ($10,500) |
| 2021 | $8,600 | 13 | AstraZeneca UK Limited ($6,100) |
| 2020 | $9,200 | 10 | AstraZeneca UK Limited ($6,600) |
| 2019 | $101,600 | 12 | Merck Sharp & Dohme Corporation ($92,700) |
| 2018 | $119,300 | 7 | Merck Sharp & Dohme Corporation ($112,300) |
| 2017 | $19,000 | 5 | Merck Sharp & Dohme Corporation ($17,400) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $18,250.00 | General |
| Category: Respiratory | ||||||
| 07/30/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| Category: Respiratory | ||||||
| 07/02/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Respiratory | ||||||
| 05/28/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Respiratory | ||||||
| 04/30/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Respiratory | ||||||
| 04/02/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| Category: Respiratory | ||||||
| 03/05/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $27,000.00 | General |
| Category: Respiratory | ||||||
| 01/30/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $21,750.00 | General |
| Category: Respiratory | ||||||
| 01/02/2024 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Respiratory | ||||||
| 10/31/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $17,000.00 | General |
| Category: Respiratory | ||||||
| 08/15/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 08/01/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 05/30/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Respiratory | ||||||
| 03/28/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 02/28/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Respiratory | ||||||
| 01/31/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 12/27/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 09/29/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Respiratory | ||||||
| 09/01/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Respiratory | ||||||
| 08/04/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Respiratory | ||||||
| 06/30/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Respiratory | ||||||
| 06/02/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Respiratory | ||||||
| 05/05/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Respiratory | ||||||
| 03/24/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Respiratory | ||||||
| 03/10/2022 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IPF-001 Phase 2 (CC-90001-IPF-001) (BMS Study Number: IM043-P04) (CC-90001-IPF-001) | Celgene Corporation | $8,900 | 1 |
| CC-90001-IPF-001 - IPF-001 Phase 2 (CC-90001-IPF-001) (BMS Study Number: IM043-P04) | Celgene Corporation | $7,000 | 1 |
| IPF-001 Phase 2 (CC-90001-IPF-001) (BMS Study Number: IM043-P04) | Celgene Corporation | $2,600 | 1 |
| CC-90001-IPF-001 | Celgene Corporation | $1,600 | 1 |
| A Phase 2, 24-Week, Randomized, Double-blind, Plac | Celgene Corporation | $1,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 6,393 | 13,376 | $3.2M | $189,720 |
| 2022 | 8 | 5,559 | 10,480 | $2.7M | $162,722 |
| 2021 | 8 | 5,038 | 9,259 | $2.2M | $140,501 |
| 2020 | 8 | 5,183 | 9,210 | $2.2M | $153,616 |
Total Patients
22,173
Total Services
42,325
Medicare Billing
$646,559
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 71250 | Ct scan of chest without contrast | Office | 2023 | 666 | 746 | $1.1M | $53,778 | 4.7% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 860 | 960 | $585,015 | $35,201 | 6.0% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 474 | 495 | $419,536 | $30,964 | 7.4% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 2,012 | 3,502 | $231,132 | $21,524 | 9.3% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 390 | 415 | $271,825 | $16,163 | 5.9% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 159 | 199 | $335,565 | $14,838 | 4.4% |
| 71046 | X-ray of chest, 2 views | Facility | 2023 | 1,472 | 1,704 | $134,616 | $12,434 | 9.2% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 270 | 282 | $22,440 | $1,904 | 8.5% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Facility | 2023 | 30 | 30 | $6,743 | $1,464 | 21.7% |
| 74174 | Ct scan of blood vessels of abdomen and pelvis with contrast | Facility | 2023 | 12 | 12 | $15,360 | $867.79 | 5.6% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 48 | 5,031 | $11,175 | $582.14 | 5.2% |
| 71250 | Ct scan of chest without contrast | Office | 2022 | 581 | 643 | $919,613 | $43,038 | 4.7% |
| 71250 | Ct scan of chest without contrast | Facility | 2022 | 779 | 857 | $522,770 | $31,644 | 6.1% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2022 | 467 | 483 | $391,230 | $30,595 | 7.8% |
| 71045 | X-ray of chest, 1 view | Facility | 2022 | 1,912 | 3,358 | $221,628 | $20,358 | 9.2% |
| 71260 | Ct scan of chest with contrast | Facility | 2022 | 291 | 308 | $201,740 | $12,440 | 6.2% |
| 71260 | Ct scan of chest with contrast | Office | 2022 | 117 | 141 | $244,585 | $10,891 | 4.5% |
| 71046 | X-ray of chest, 2 views | Facility | 2022 | 1,097 | 1,278 | $100,962 | $9,338 | 9.2% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 245 | 255 | $20,311 | $1,674 | 8.2% |
| 74174 | Ct scan of blood vessels of abdomen and pelvis with contrast | Facility | 2022 | 20 | 20 | $25,600 | $1,605 | 6.3% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Facility | 2022 | 17 | 17 | $1,530 | $849.57 | 55.5% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2022 | 33 | 3,120 | $8,232 | $289.28 | 3.5% |
| 71250 | Diagnostic ct scan of chest | Facility | 2021 | 764 | 846 | $517,412 | $31,009 | 6.0% |
| 71275 | Ct scan of blood vessels in chest with contrast | Facility | 2021 | 413 | 433 | $350,730 | $28,478 | 8.1% |
| 71250 | Diagnostic ct scan of chest | Office | 2021 | 383 | 422 | $570,853 | $28,385 | 5.0% |
About Dr. Jeffrey Kanne, M.D
Dr. Jeffrey Kanne, M.D is a Diagnostic Radiology healthcare provider based in Madison, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639186463.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Kanne, M.D has received a total of $376,050 in payments from pharmaceutical and medical device companies, with $87,250 received in 2024. These payments were reported across 72 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($354,450).
As a Medicare-enrolled provider, Kanne has provided services to 22,173 Medicare beneficiaries, totaling 42,325 services with total Medicare billing of $646,559. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Madison, WI
- Active Since 08/02/2006
- Last Updated 02/01/2021
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1639186463
Products in Payments
- NOXAFIL (Drug) $222,400
- FASENRA (Biological) $125,450
- CC-90001 (Drug) $17,500
- FASENRA (Drug) $6,600
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Madison
James Hinshaw, Md, MD
Diagnostic Radiology — Payments: $465,406
Diagnostic Radiology $465,406
Perry Pickhardt, Md, MD
Diagnostic Radiology — Payments: $117,053
Diagnostic Radiology $117,053
Dr. Thomas Gallagher, M.d, M.D
Diagnostic Radiology — Payments: $90,687
Diagnostic Radiology $90,687
Dania Daye, M.d., Ph.d, M.D., PH.D
Diagnostic Radiology — Payments: $69,316
Diagnostic Radiology $69,316
Sina Meisamy, Md, MD
Diagnostic Radiology — Payments: $64,425
Diagnostic Radiology $64,425
Ali Pirasteh
Diagnostic Radiology — Payments: $37,912
Diagnostic Radiology $37,912